Intelligence / MOTS-c

MOTS-c

Prescription Only
Mitochondrial Peptide
Schedule
S4
Prescription Only
Enforcement
Monitoring
Medium Risk
Providers
4
Access: Emerging
Key Facts
Schedule 4 - Prescription Only
Mitochondrial-derived peptide
4 identified Australian providers
Limited prescriber familiarity
Growing interest in Australian market

Overview

MOTS-c is a mitochondrial-derived peptide encoded within the 12S rRNA gene. It is an emerging peptide in the Australian market with limited prescriber familiarity. Not yet widely compounded, but interest is growing.

Australian Scheduling

Schedule 4 (Prescription Only). TGA is monitoring this peptide as its use grows. Limited compounding infrastructure currently in place.

Access Pathway

Available through a small number of telehealth providers. 4 identified Australian providers. Prescriber familiarity is limited, and not all compounding pharmacies have established formulations.

Regulatory Notice

For informational purposes only. TGA scheduling may change without notice. All Schedule 4 peptides require a valid prescription from a registered Australian medical practitioner. This site does not sell, supply, or facilitate access to therapeutic goods. Data compiled from TGA SUSMP, public provider directories, and publicly available review platforms.

News & Updates20 items
Mitochondrial-derived peptides (MDPs) activated by physical exercise as therapeutic targets for metabolic disorders: A systematic review
Physiol Int25 Aug 2026
MOTS-c in sepsis-induced cardiomyopathy: Mechanisms and translational potential
Eur J Pharmacol23 Aug 2026
MOTS-c is a mitochondrial-encoded interferon-linked host defense peptide
Elife18 Aug 2026
Mitochondria-derived peptide hydrogel augments mitochondrial transplantation for promoting cardiac repair via macrophage metabolic reprogramming
Bioact Mater14 Aug 2026
Emerging regulators of human physiology and disease; sORF-encoded microproteins
Epigenomics10 Aug 2026
Mitochondrial peptide MOTS-c suppresses systemic and cardiac inflammasome activation in a diabetic rat model
Exp Physiol1 Aug 2026
Circulating mitochondrial-derived microproteins at rest and in response to an acute bout of endurance exercise in individuals with cerebral palsy
Exp Physiol1 Aug 2026
MOTS-c attenuates hyperoxia-induced neonatal cardiac injury by inhibiting oxeiptosis via maintaining the KEAP1-PGAM5 interaction
Life Sci1 Aug 2026
LAT1-mediated delivery of engineered R13A-MOTS-c attenuates radiation-induced lung injury via Nrf2 activation and mitochondrial protection
Redox Biol1 July 2026
Mitochondrial-derived peptide MOTS-c targets SLC7A11 to preserve spermatogenesis by suppressing ferroptosis
Free Radic Biol Med1 July 2026
MOTS-c: How a secreted mitochondrial microprotein may become a potential treatment for inflammatory lung diseases
J Transl Med4 June 2026
MOTS-c preserves mitochondrial subpopulation bioenergetics and genome integrity to attenuate cardiac ischemia reperfusion injury
Mol Biol Rep2 June 2026
Elevated Serum Nardilysin Is Inversely Associated with Cardiovascular Disease in Kidney Transplant Recipients
Kidney Blood Press Res21 May 2026
MOTS-c, a mitochondrial-derived peptide, ameliorates lysosomal membrane permeability and improves survival of soft tissue transplantation
Autophagy19 May 2026
The Association Between Serum MOTS-c Levels and Myocardial Ischemia-Reperfusion Injury in Patients with Acute Myocardial Infarction: A Cross-Sectional Study
Biomedicines17 Apr 2026
Are serum MOTS-c levels and MOTS-c m.1382A>C polymorphism related to polycystic ovary syndrome?
Arch Endocrinol Metab7 Apr 2026
MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation
PMC1 Feb 2023
Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging
PMC1 Jan 2023
Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c
Nature1 Aug 2021
MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline
Nature20 Jan 2021

Are You a Practitioner?

List your clinic for free and reach patients actively searching for legal peptide access in Australia.